Publications by authors named "Sbidian E"
Background: Epidermal necrolysis (EN) is a rare and severe condition, characterized by a diffuse skin and mucosal detachment and mainly induced by drugs. Literature is scarce regarding the rate of recurrences and culprit drug re-exposure.
Objectives: To assess the rate of EN recurrences as well as high notoriety drugs re-exposures in patients with EN.
Probing into functional decline among bullous pemphigoid patients: Letter in reply.
J Eur Acad Dermatol Venereol
January 2025
Background: The lack of evidence under routine clinical settings limited the widespread adoption of adalimumab biosimilars for psoriasis treatment.
Objective: This study compared the drug survival and safety of adalimumab biosimilars to Humira for psoriasis treatment.
Methods: We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM).
Background And Aim: The involvement of mucosa associated lymphoid tissues (MALT) in the development of an autoimmune response in the skin is unclear and unstudied. In this study we sought to assess the relationship between removal of MALT tissues (MALTectomy) and the risk of development of psoriasis (overall or moderate-to-severe).
Methods: We conducted a prospective observational study based on E3N, a French cohort composed of 98 995 women born between 1925 and 1950 and insured by the health insurance of the national education system (MGEN).
Article Synopsis
- The study investigates the incidence and mortality rates of epidermal necrolysis (EN), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), analyzing data from adult patients in the French Health System over nine years.
- It found an in-hospital mortality rate of 19% and a postdischarge mortality rate of 15%, leading to an overall mortality of 34% among patients.
- Key factors influencing in-hospital mortality include age, history of cancer, dementia, liver disease, and the severity of EN, with cancer and liver disease also impacting postdischarge mortality.
Background: Mycosis fungoides (MF) usually has an indolent course. However, some patients develop more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest an unfavourable prognosis.
View Article and Find Full Text PDFObjectives: To assess the potential impact of targeted therapies for psoriatic arthritis (PsA) on symptomatic treatments (non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics), methotrexate and mood disorder treatments and on hospitalisation and sick leave.
Methods: Using the French health insurance database, this nationwide cohort study included adults with PsA who were new users (not in the year before the index date) of targeted therapies for ≥9 months during 2015-2021. Main endpoints were difference in proportion of users of associated treatments, hospitalisations and sick leaves between 3 and 9 months after and 6 months before targeted therapy initiation.
Functional decline among bullous pemphigoid patients: A retrospective monocentric cohort study.
J Eur Acad Dermatol Venereol
July 2024
Background: Bullous pemphigoid (BP) affects older patients with numerous comorbidities. The impact of BP on patient autonomy remains poorly understood.
Objectives: To assess the frequency and factors associated with functional decline (FD) in BP.
Objectives: To explore the association between industry funding and network meta-analyses' (NMAs) conclusion, and the use in Clinical Practice Guidelines (CPGs) of NMAs.
Study Design And Setting: This was an overview of NMAs and CPGs. We searched PubMed/MEDLINE, Epistemonikos, and several guideline databases up to February 18th 2023.
Article Synopsis
- Epidermal necrolysis (EN) includes severe conditions like Stevens-Johnson syndrome and is primarily drug-induced, with notable differences in incidence and outcomes between children and adults.
- A study analyzed data from the French Health System to compare EN cases in both demographics, examining incidence, suspected drug exposure, and mortality rates.
- Results showed that EN is less common in children (1.5 cases/million) compared to adults (2.6 cases/million), with children having a lower rate of drug exposure before onset and significantly lower mortality (1.4% vs. 19.4%).
Objectives: Incomplete reporting of safety outcomes in quality and availability of safety reporting in published articles of randomized controlled trials (RCTs) were described in different medical areas. The number of RCTs assessing systemic treatments for psoriasis has increased considerably. Complete and precise reporting of safety is mandatory for the efficacy/harms balance evaluation.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the risk of gastrointestinal perforation (GIP) between patients using JAK inhibitors (like tofacitinib and baricitinib) and those using the TNF inhibitor adalimumab in individuals with rheumatic diseases.
- Researchers analyzed data from a large cohort (39,758 patients) sourced from the French national health database from July 2017 to December 2021, tracking GIP occurrences until May 2022.
- Results showed that the incidence rates of GIP were similar between the two groups, with no significant difference in risk levels, suggesting that both treatments are comparable concerning this rare but serious side effect.
Article Synopsis
- - The objective of the study was to evaluate the risk of serious infections in patients with psoriatic arthritis who were starting various targeted therapies in real-world scenarios.
- - Researchers analyzed data from over 12,000 patients and found that 3% experienced serious infections, with a notable difference in infection rates depending on the therapy used, particularly lower rates for etanercept and ustekinumab compared to adalimumab.
- - The study concluded that the overall risk of serious infections is relatively low for patients on targeted therapies for PsA, but newer users of etanercept and ustekinumab had a significantly reduced risk compared to those starting adalimumab, while the other treatments did not show significant differences.
Article Synopsis
- The study aimed to compare the persistence and safety of biosimilar medications versus their originator counterparts for infliximab, etanercept, and adalimumab in various medical conditions.
- Researchers utilized extensive data from the French National Health Data System, tracking nearly 87,000 patients from the launch of biosimilars in 2015, 2016, and 2018 until June 2021, with a follow-up period of one year.
- Results indicated no significant difference in treatment discontinuation rates or safety events, suggesting biosimilars are as safe and effective as their originators across all licensed indications.
Background: Sex differences in phenotype presentation, disease trajectory and treatment response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of targeted therapies differentially affect men and women with PsA remains unclear.
Objectives: To assess the effect of sex on the long-term persistence of each class of targeted therapies in PsA.
Psoriasis is one of the most common immune-mediated inflammatory diseases (IMIDs). Living in a rural environment during childhood is associated with a decreased risk of certain IMIDs, like asthma, in adulthood. However, its role in other IMIDs, such as psoriasis is still unclear.
View Article and Find Full Text PDFBackground: Many biologics are available for psoriasis and have been compared in real-life studies based on their persistence (i.e. time between initiation and discontinuation).
View Article and Find Full Text PDF